Company Announcement Quarterly Activities Report and 4C to 31 March 2022 April 29, 2022April 29, 2022
Company Announcement Positive Results for Phase II Topical CBD Osteoarthritis Study March 29, 2022March 29, 2022
Company Announcement Dosing Commences for CBD Topical Osteoarthritis Study March 1, 2022March 2, 2022
Company Announcement New Product License and Supply Agreement for US recreational cannabis market February 2, 2022February 2, 2022
Company Announcement Results for Phase I human clinical trial of CBD soft-gel product December 8, 2021December 8, 2021
Company Announcement Ethics Approval for CBD Topical Osteoarthritis Study October 21, 2021October 21, 2021
Company Announcement Dosing commences for Phase I human clinical trial October 4, 2021October 4, 2021
